Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy

Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Robert, Arshad, Junaid, Palacio, Sofia, Mudad, Raja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372006/
https://www.ncbi.nlm.nih.gov/pubmed/30804663
http://dx.doi.org/10.2147/DDDT.S147499
Descripción
Sumario:Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC.

Ejemplares similares